| Sep'19 | Sep'18 | Sep'17 | Sep'16 | Sep'15 | ||
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
Net loss | ||||||
-34,523 | -30,091 | -38,849 | -53,301 | -47,393 | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
3,361 | 3,054 | 2,692 | 2,394 | 1,824 | ||
Loss on extinguishment of debt | ||||||
-607 | -1,252 | - | - | - | ||
Non-cash interest expense | ||||||
1,314 | 1,315 | 4,014 | 13 | 12 | ||
Stock-based compensation | ||||||
1,313 | 1,985 | 8,571 | 12,450 | 11,177 | ||
Change in fair value of warrant liability | ||||||
-2,438 | -1,047 | -3,158 | - | - | ||
Loss on disposal of property and equipment | ||||||
- | - | -61 | -13 | - | ||
Loss on lease termination | ||||||
- | -4,173 | - | - | - | ||
Impairment of property and equipment | ||||||
11,300 | 0 | - | - | - | ||
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
- | - | - | -20 | 20 | ||
Prepaid expenses and other current assets | ||||||
3,245 | 1,419 | -2,607 | 1,533 | 1,021 | ||
Other assets | ||||||
87 | -1 | -112 | -57 | 322 | ||
Accounts payable | ||||||
-1,331 | -6,714 | 5,727 | -5,326 | 6,580 | ||
Accrued expenses | ||||||
-482 | -1,664 | 893 | 1,154 | 2,240 | ||
Income taxes payable | ||||||
3 | -496 | 497 | 100 | 190 | ||
Deferred revenue | ||||||
-8,146 | -3,057 | 1,188 | -1,979 | 530 | ||
Other liabilities | ||||||
94 | -331 | 135 | 455 | 1 | ||
Net cash used in operating activities | ||||||
-32,289 | -33,039 | -15,505 | - | - | ||
INVESTING ACTIVITIES | ||||||
Net cash used in operating activities | ||||||
- | - | - | -45,482 | -27,476 | ||
Purchase of property and equipment | ||||||
437 | 2,781 | 292 | 1,098 | 8,804 | ||
Net cash used in investing activities | ||||||
-437 | -2,781 | -292 | - | - | ||
FINANCING ACTIVITIES | ||||||
Net cash used in investing activities | ||||||
- | - | - | -1,098 | -8,804 | ||
Repurchase of Series A redeemable preferred stock | ||||||
- | - | - | - | 226 | ||
Proceeds from the sale of common stock, net of offering costs | ||||||
45,964 | 14,695 | 1,607 | 16,137 | 41,249 | ||
Payment of debt issuance costs | ||||||
- | - | 40 | - | - | ||
Proceeds from subscriptions receivable | ||||||
- | - | - | 4,280 | - | ||
Proceeds from issuance of Series A convertible preferred stock | ||||||
- | - | 3,262 | - | - | ||
Proceeds from issuance of Series A convertible preferred stock | ||||||
- | 21,737 | - | - | - | ||
Proceeds from the sale of equity in noncontrolling interest | ||||||
- | - | - | - | 401 | ||
Proceeds from the sale of senior secured notes and detachable warrants | ||||||
- | - | 15,000 | - | 10,880 | ||
Proceeds from exercise of common stock warrants | ||||||
4 | - | 253 | - | - | ||
Repayment of stockholder notes | ||||||
- | - | - | 11,601 | 7,888 | ||
Change in restricted cash | ||||||
- | - | 216 | -2 | - | ||
Change in restricted cash | ||||||
- | - | - | - | 2 | ||
Payments of capital leases obligations | ||||||
526 | 862 | 991 | 884 | 686 | ||
Proceeds from debt | ||||||
- | - | - | 200 | - | ||
Repayment of debt | ||||||
6,417 | 127 | 2,677 | 1,059 | 725 | ||
Payment of financing costs | ||||||
- | 1,089 | - | - | - | ||
Proceeds from sale of common stock units in connection with initial public offering and private placement | ||||||
- | - | - | 37,074 | - | ||
Payment of financing costs | ||||||
- | - | - | 4,637 | - | ||
Net cash provided by financing activities | ||||||
39,025 | 34,352 | 16,630 | - | - | ||
Net decrease in cash | ||||||
6,298 | -1,468 | - | - | - | ||
Proceeds from related party receivable | ||||||
- | - | - | 826 | - | ||
Deconsolidation of Sonnet Biotherapeutics, Inc. | ||||||
- | - | - | 401 | - | ||
Payment of employee tax withholdings related to the vesting of restricted stock | ||||||
- | - | - | 71 | - | ||
Net cash provided by financing activities | ||||||
- | - | - | 39,861 | 43,002 | ||
Net increase in cash | ||||||
- | - | 833 | -6,719 | 6,721 | ||
Supplemental disclosure of cash flow information | ||||||
Cash paid for interest | ||||||
- | - | - | - | 1,402 | ||
Cash paid for interest | ||||||
2,794 | 109 | 1,339 | 2,061 | - | ||
Cash paid for income taxes | ||||||
- | - | 1 | 3 | 2 | ||
Supplemental schedule of noncash investing activities: | ||||||
Purchases of property and equipment in accounts payable and accrued expenses | ||||||
- | 816 | 68 | 634 | - | ||
Purchases of property and equipment in accounts payable and accrued expenses | ||||||
- | - | - | - | -2,770 | ||
Supplemental schedule of noncash financing activities: | ||||||
Senior secured notes and accrued interest converted into common stock | ||||||
-401 | - | - | - | - | ||
Unsecured notes and accrued interest converted into common stock | ||||||
-480 | - | - | - | - | ||
Accretion of redeemable common stock | ||||||
- | - | - | 2,463 | 4,306 | ||
Deemed dividend upon repurchase of Series A redeemable preferred stock in excess of carrying value | ||||||
- | - | - | - | -1,298 | ||
Issuance of Series B convertible preferred stock upon conversion of senior secured notes, net of unamortized debt discount | ||||||
- | 1,409 | - | 11,894 | -4,280 | ||
Reclassification of equity classified stock-based compensation | ||||||
- | - | - | 15,118 | - | ||
Distribution of common stock in Sonnet Biotherapeutics, Inc. to stockholders | ||||||
- | - | - | - | -221 | ||
Issuance of capital lease obligations in connection with purchase of property and equipment | ||||||
48 | 4,444 | 62 | 100 | 2,603 | ||
Change in fair value of convertible senior secured notes warrants recorded as debt discount | ||||||
1,466 | - | - | - | - | ||
Series A and A-1 convertible preferred stock dividends | ||||||
624 | 1,886 | 16 | - | - | ||
Settlement of Series A and A-1 convertible preferred stock dividends upon issuance of Series A and A-1 convertible preferred stock | ||||||
624 | 1,903 | - | - | - | ||
Deferred offering costs and common stock issuance costs in accounts payable and accrued expenses | ||||||
- | - | 630 | - | 2,310 | ||
Accrued directors' fees settled in fully vested stock options | ||||||
49 | - | - | - | - | ||